Results 171 to 180 of about 78,686 (205)
Some of the next articles are maybe not open access.
Actin’ against BRAF inhibitors
Science Signaling, 2016Blocking actin polymerization prevents YAP and TAZ activation and resistance to BRAF inhibitors in melanoma.
openaire +1 more source
BRAF and MEK inhibitors in BRAF-mutant melanoma
The Lancet Oncology, 2012Patients with melanoma and the Val600 BRAF mutation benefi t from combined inhibition of BRAF and MEK, according to a new study. Selective BRAF inhibitors such as dabrafenib and MEK inhibitors such as trametinib have individually been shown to increase progressionfree survival (PFS) and overall survival in Val600 BRAF-mutant melanoma.
openaire +1 more source
BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma
Melanoma Research, 2015In around 50% of melanomas, the BRAF V600 mutation, resulting in an activation of the MAP kinase pathway, is detected. BRAF inhibitors have shown remarkable activity on the disease. However, efficacy is short-lived in most cases, with a median disease-free survival of 6 months.
Jennifer, Roux +12 more
openaire +2 more sources
BRAF Inhibitor-Induced Panniculitis
Clinical Nuclear Medicine, 2016BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules.
Stephen M, Broski +3 more
openaire +2 more sources
BRAF Inhibitor Induced Verrucal Keratosis
The American Journal of Dermatopathology, 2014Rachael, Anforth, Pablo, Fernandez-Penas
openaire +2 more sources
Response to BRAF and MEK Inhibitors in BRAF Thr599dup–Mutated Melanoma
JCO Precision Oncology, 2022Marion Oberlé +11 more
openaire +2 more sources
Cutaneous Reactions to BRAF Inhibitors
2015BRAF inhibitors, specifically vemurafenib and dabrafenib, are emerging as first-line treatment for unresectable and/or metastatic BRAF mutated melanoma due to their superior efficacy and improved survival statistics. While better tolerated than previously used treatment options, they carry high rates of cutaneous reactions, with most BRAF-inhibitor ...
openaire +1 more source
BRAF inhibitor therapy of primary ameloblastoma
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016Serena, Tan +4 more
openaire +2 more sources